Single low-dose rHuIL-12 safely triggers multilineage hematopoietic and immune-mediated effects

Experimental Hematology and Oncology

Volumn 3, Issue 1, 2014, Pages

  Gokhale, Mamata S ^a   Vainstein, Vladimir ^a   Tom, Jamie ^a   Thomas, Simmy ^a   Lawrence, Chris E ^a   Gluzman Poltorak, Zoya ^a   Siebers, Nicholas ^b   Basile, Lena A ^a  

^a Neumedicines Inc   (United States)

^b 206 Carnegie Center   (United States)

Author keywords

Cancer; Hematopoiesis; HSARS; Human; IL 12

Indexed keywords

ALANINE AMINOTRANSFERASE; CD34 ANTIGEN; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; RECOMBINANT INTERLEUKIN 12;

ABDOMINAL DISTENSION; ABNORMAL SENSATION; ADULT; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; BACKACHE; BLOOD TOXICITY; CELLULAR IMMUNITY; CHILL; CONTROLLED STUDY; CYTOPENIA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; EXTRACELLULAR SPACE; FATIGUE; FEMALE; HEADACHE; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN EXPERIMENT; HYPESTHESIA; IMMUNOGENICITY; IMMUNOREACTIVITY; INFESTATION; INJECTION SITE BLEEDING; INJECTION SITE ERYTHEMA; INJECTION SITE INFECTION; INJECTION SITE PAIN; INJECTION SITE REACTION; INJECTION SITE SWELLING; LEUKOPENIA; LOW DRUG DOSE; LYMPHADENITIS; LYMPHOCYTE COUNT; LYMPHOCYTOPENIA; MALAISE; MALE; MAXIMUM PLASMA CONCENTRATION; MUSCULOSKELETAL STIFFNESS; MYALGIA; NATURAL KILLER CELL; NAUSEA; NECK PAIN; NEUTROPENIA; NEUTROPHIL COUNT; NORMAL HUMAN; ORAL PARESTHESIA; PAIN; PARESTHESIA; PHASE 1 CLINICAL TRIAL; PHOTOPHOBIA; PRESYNCOPE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RETICULOCYTE COUNT; SINGLE DRUG DOSE; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TIME TO MAXIMUM PLASMA CONCENTRATION; TONSILLITIS; UNSPECIFIED SIDE EFFECT; VIRUS INFECTION; VOMITING;

EID: 84978024382     PISSN: None     EISSN: 21623619     Source Type: Journal    
DOI: 10.1186/2162-3619-3-11     Document Type: Article

References (65)

1. Bellone G, Trinchieri G. Dual stimulatory and inhibitory effect of NK cell stimulatory factor/IL-12 on human hematopoiesis. J Immunol 1994, 153:930-937.
2. Hirayama F, Katayama N, Neben S, Donaldson D, Nickbarg EB, Clark SC, Ogawa M. Synergistic interaction between interleukin-12 and steel factor in support of proliferation of murine lymphohematopoietic progenitors in culture. Blood 1994, 83:92-98.
3. Jacobsen SE, Veiby OP, Smeland EB. Cytotoxic lymphocyte maturation factor (interleukin 12) is a synergistic growth factor for hematopoietic stem cells. J Exp Med 1993, 178:413-418. 10.1084/jem.178.2.413, 2191103, 7688022.
4. Ploemacher RE, van Soest PL, Boudewijn A, Neben S. Interleukin-12 enhances interleukin-3 dependent multilineage hematopoietic colony formation stimulated by interleukin-11 or steel factor. Leukemia 1993, 7:1374-1380.
5. Ploemacher RE, van Soest PL, Voorwinden H, Boudewijn A. Interleukin-12 synergizes with interleukin-3 and steel factor to enhance recovery of murine hemopoietic stem cells in liquid culture. Leukemia 1993, 7:1381-1388.
6. Basile LA, Ellefson D, Gluzman-Poltorak Z, Junes-Gill K, Mar V, Mendonca S, Miller JD, Tom J, Trinh A, Gallaher TK. HemaMax, a Recombinant Human Interleukin-12. Is a potent mitigator of acute radiation injury in mice and non-human primates. PLoS One 2012, 7:e30434. 10.1371/journal.pone.0030434, 3286478, 22383962.
7. Dybedal I, Larsen S, Jacobsen SE. IL-12 directly enhances in vitro murine erythropoiesis in combination with IL-4 and stem cell factor. J Immunol 1995, 154:4950-4955.
8. Brunda MJ. Interleukin-12. J Leukoc Biol 1994, 55:280-288.
9. Kobayashi M, Fitz L, Ryan M, Hewick RM, Clark SC, Chan S, Loudon R, Sherman F, Perussia B, Trinchieri G. Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes. J Exp Med 1989, 170:827-845. 10.1084/jem.170.3.827, 2189443, 2504877.
10. Trudeau C, Cotreau MM, Stonis L, Dykstra KH, Oestreicher JL, Strahs A, Dorner AJ, Van Cleave VH, Trepicchio WL, Schwertschlag US. A single administration of recombinant human interleukin-12 is associated with increased expression levels of interferon-gamma and signal transducer and activator of transcription in healthy subjects. J Clin Pharmacol 2005, 45:649-658. 10.1177/0091270005276116, 15901746.
11. Wolf SF, Sieburth D, Sypek J. Interleukin 12: a key modulator of immune function. Stem Cells 1994, 12:154-168. 10.1002/stem.5530120203, 7911046.
12. Wolf SF, Temple PA, Kobayashi M, Young D, Dicig M, Lowe L, Dzialo R, Fitz L, Ferenz C, Hewick RM. Cloning of cDNA for natural killer cell stimulatory factor, a heterodimeric cytokine with multiple biologic effects on T and natural killer cells. J Immunol 1991, 146:3074-3081.
13. Brunda MJ, Luistro L, Warrier RR, Wright RB, Hubbard BR, Murphy M, Wolf SF, Gately MK. Antitumor and antimetastatic activity of interleukin 12 against murine tumors. J Exp Med 1993, 178:1223-1230. 10.1084/jem.178.4.1223, 2191194, 8104230.
14. Nastala CL, Edington HD, McKinney TG, Tahara H, Nalesnik MA, Brunda MJ, Gately MK, Wolf SF, Schreiber RD, Storkus WJ. Recombinant IL-12 administration induces tumor regression in association with IFN-gamma production. J Immunol 1994, 153:1697-1706.
15. Bi Z, Quandt P, Komatsu T, Barna M, Reiss CS. IL-12 promotes enhanced recovery from vesicular stomatitis virus infection of the central nervous system. J Immunol 1995, 155:5684-5689.
16. Cavanaugh VJ, Guidotti LG, Chisari FV. Interleukin-12 inhibits hepatitis B virus replication in transgenic mice. J Virol 1997, 71:3236-3243. 191456, 9060687.
17. Schwarze J, Hamelmann E, Cieslewicz G, Tomkinson A, Joetham A, Bradley K, Gelfand EW. Local treatment with IL-12 is an effective inhibitor of airway hyperresponsiveness and lung eosinophilia after airway challenge in sensitized mice. J Allergy Clin Immunol 1998, 102:86-93. 10.1016/S0091-6749(98)70058-2, 9679851.
18. Altare F, Lammas D, Revy P, Jouanguy E, Doffinger R, Lamhamedi S, Drysdale P, Scheel-Toellner D, Girdlestone J, Darbyshire P, Wadhwa M, Dockrell H, Salmon M, Fischer A, Durandy A, Casanova JL, Kumararatne DS. Inherited interleukin 12 deficiency in a child with bacille Calmette-Guerin and Salmonella enteritidis disseminated infection. J Clin Invest 1998, 102:2035-2040. 10.1172/JCI4950, 509157, 9854038.
19. de Jong R, Altare F, Haagen IA, Elferink DG, Boer T, van Breda Vriesman PJ, Kabel PJ, Draaisma JM, van Dissel JT, Kroon FP, Casanova JL, Ottenhoff TH. Severe mycobacterial and Salmonella infections in interleukin-12 receptor-deficient patients. Science 1998, 280:1435-1438. 10.1126/science.280.5368.1435, 9603733.
20. Goebel A, Kavanagh E, Lyons A, Saporoschetz IB, Soberg C, Lederer JA, Mannick JA, Rodrick ML. Injury induces deficient interleukin-12 production, but interleukin-12 therapy after injury restores resistance to infection. Ann Surg 2000, 231:253-261. 10.1097/00000658-200002000-00015, 1420994, 10674618.
21. Colombo MP, Trinchieri G. Interleukin-12 in anti-tumor immunity and immunotherapy. Cytokine Growth Factor Rev 2002, 13:155-168. 10.1016/S1359-6101(01)00032-6, 11900991.
22. Little RF, Pluda JM, Wyvill KM, Rodriguez-Chavez IR, Tosato G, Catanzaro AT, Steinberg SM, Yarchoan R. Activity of subcutaneous interleukin-12 in AIDS-related Kaposi sarcoma. Blood 2006, 107:4650-4657. 10.1182/blood-2005-11-4455, 1475826, 16507779.
23. Rook AH, Wood GS, Yoo EK, Elenitsas R, Kao DM, Sherman ML, Witmer WK, Rockwell KA, Shane RB, Lessin SR, Vonderheid EC. Interleukin-12 therapy of cutaneous T-cell lymphoma induces lesion regression and cytotoxic T-cell responses. Blood 1999, 94:902-908.
24. Younes A, Pro B, Robertson MJ, Flinn IW, Romaguera JE, Hagemeister F, Dang NH, Fiumara P, Loyer EM, Cabanillas FF, McLaughlin PW, Rodriguez MA, Samaniego F. Phase II clinical trial of interleukin-12 in patients with relapsed and refractory non-Hodgkin's lymphoma and Hodgkin's disease. Clin Cancer Res 2004, 10:5432-5438. 10.1158/1078-0432.CCR-04-0540, 15328181.
25. Gollob JA, Mier JW, Veenstra K, McDermott DF, Clancy D, Clancy M, Atkins MB. Phase I trial of twice-weekly intravenous interleukin 12 in patients with metastatic renal cell cancer or malignant melanoma: ability to maintain IFN-gamma induction is associated with clinical response. Clin Cancer Res 2000, 6:1678-1692.
26. Gollob JA, Veenstra KG, Parker RA, Mier JW, McDermott DF, Clancy D, Tutin L, Koon H, Atkins MB. Phase I trial of concurrent twice-weekly recombinant human interleukin-12 plus low-dose IL-2 in patients with melanoma or renal cell carcinoma. J Clin Oncol 2003, 21:2564-2573. 10.1200/JCO.2003.12.119, 12829677.
27. Chen T, Burke KA, Zhan Y, Wang X, Shibata D, Zhao Y. IL-12 facilitates both the recovery of endogenous hematopoiesis and the engraftment of stem cells after ionizing radiation. Exp Hematol 2007, 35:203-213. 10.1016/j.exphem.2006.10.002, 17258069.
28. Guidance for Industry: Animal Models - Essential Elements to Address Efficacy Under the Animal Rule. 2009, U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER).
29. Motzer RJ, Rakhit A, Schwartz LH, Olencki T, Malone TM, Sandstrom K, Nadeau R, Parmar H, Bukowski R. Phase I trial of subcutaneous recombinant human interleukin-12 in patients with advanced renal cell carcinoma. Clin Cancer Res 1998, 4:1183-1191.
30. Ohno R, Yamaguchi Y, Toge T, Kinouchi T, Kotake T, Shibata M, Kiyohara Y, Ikeda S, Fukui I, Gohchi A, Sugiyama Y, Saji S, Hazama S, Oka M, Ohnishi Y, Ohhashi Y, Tsukagoshi S, Taguchi T. A dose-escalation and pharmacokinetic study of subcutaneously administered recombinant human interleukin 12 and its biological effects in Japanese patients with advanced malignancies. Clin Cancer Res 2000, 6:2661-2669.
31. Guidance for Industry: Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials. 2007, A Notice by the Food and Drug Administration.
32. Portielje JE, Kruit WH, Schuler M, Beck J, Lamers CH, Stoter G, Huber C, de Boer-Dennert M, Rakhit A, Bolhuis RL, Aulitzky WE. Phase I study of subcutaneously administered recombinant human interleukin 12 in patients with advanced renal cell cancer. Clin Cancer Res 1999, 5:3983-3989.
33. Portielje JE, Lamers CH, Kruit WH, Sparreboom A, Bolhuis RL, Stoter G, Huber C, Gratama JW. Repeated administrations of interleukin (IL)-12 are associated with persistently elevated plasma levels of IL-10 and declining IFN-gamma, tumor necrosis factor-alpha, IL-6, and IL-8 responses. Clin Cancer Res 2003, 9:76-83.
34. Rakhit A, Yeon MM, Ferrante J, Fettner S, Nadeau R, Motzer R, Bukowski R, Carvajal DM, Wilkinson VL, Presky DH, Magram J, Gately MK. Down-regulation of the pharmacokinetic-pharmacodynamic response to interleukin-12 during long-term administration to patients with renal cell carcinoma and evaluation of the mechanism of this " adaptive response" in mice. Clin Pharmacol Ther 1999, 65:615-629. 10.1016/S0009-9236(99)90083-8, 10391667.
35. Robertson MJ, Pelloso D, Abonour R, Hromas RA, Nelson RP, Wood L, Cornetta K. Interleukin 12 immunotherapy after autologous stem cell transplantation for hematological malignancies. Clin Cancer Res 2002, 8:3383-3393.
36. Sosman JA, Verma A, Moss S, Sorokin P, Blend M, Bradlow B, Chachlani N, Cutler D, Sabo R, Nelson M, Bruno E, Gustin D, Viana M, Hoffman R. Interleukin 10-induced thrombocytopenia in normal healthy adult volunteers: evidence for decreased platelet production. Br J Haematol 2000, 111:104-111. 10.1046/j.1365-2141.2000.02314.x, 11091188.
37. Hamza T, Barnett JB, Li B. Interleukin 12 a key immunoregulatory cytokine in infection applications. Int J Mol Sci 2010, 11:789-806. 10.3390/ijms11030789, 2869233, 20479986.
38. Allavena P, Paganin C, Zhou D, Bianchi G, Sozzani S, Mantovani A. Interleukin-12 is chemotactic for natural killer cells and stimulates their interaction with vascular endothelium. Blood 1994, 84:2261-2268.
39. Fehniger TA, Cooper MA, Nuovo GJ, Cella M, Facchetti F, Colonna M, Caligiuri MA. CD56bright natural killer cells are present in human lymph nodes and are activated by T cell-derived IL-2: a potential new link between adaptive and innate immunity. Blood 2003, 101:3052-3057. 10.1182/blood-2002-09-2876, 12480696.
40. Maltby S, Wohlfarth C, Gold M, Zbytnuik L, Hughes MR, McNagny KM. CD34 is required for infiltration of eosinophils into the colon and pathology associated with DSS-induced ulcerative colitis. Am J Pathol 2010, 177:1244-1254. 10.2353/ajpath.2010.100191, 2928958, 20696776.
41. Suzawa K, Kobayashi M, Sakai Y, Hoshino H, Watanabe M, Harada O, Ohtani H, Fukuda M, Nakayama J. Preferential induction of peripheral lymph node addressin on high endothelial venule-like vessels in the active phase of ulcerative colitis. Am J Gastroenterol 2007, 102:1499-1509. 10.1111/j.1572-0241.2007.01189.x, 17459027.
42. Gately MK, Warrier RR, Honasoge S, Carvajal DM, Faherty DA, Connaughton SE, Anderson TD, Sarmiento U, Hubbard BR, Murphy M. Administration of recombinant IL-12 to normal mice enhances cytolytic lymphocyte activity and induces production of IFN-gamma in vivo. Int Immunol 1994, 6:157-167. 10.1093/intimm/6.1.157, 7908534.
43. Jackson JD, Yan Y, Brunda MJ, Kelsey LS, Talmadge JE. Interleukin-12 enhances peripheral hematopoiesis in vivo. Blood 1995, 85:2371-2376.
44. Mortarini R, Borri A, Tragni G, Bersani I, Vegetti C, Bajetta E, Pilotti S, Cerundolo V, Anichini A. Peripheral burst of tumor-specific cytotoxic T lymphocytes and infiltration of metastatic lesions by memory CD8+ T cells in melanoma patients receiving interleukin 12. Cancer Res 2000, 60:3559-3568.
45. Dinarello CA, Fantuzzi G. Interleukin-18 and host defense against infection. J Infect Dis 2003, 187(Suppl 2):S370-S384.
46. Gracie JA, Robertson SE, McInnes IB. Interleukin-18. J Leukoc Biol 2003, 73:213-224.
47. Anagnostou A, Liu Z, Steiner M, Chin K, Lee ES, Kessimian N, Noguchi CT. Erythropoietin receptor mRNA expression in human endothelial cells. Proc Natl Acad Sci U S A 1994, 91:3974-3978. 10.1073/pnas.91.9.3974, 43705, 8171022.
48. Brines M, Cerami A. Emerging biological roles for erythropoietin in the nervous system. Nat Rev Neurosci 2005, 6:484-494. 10.1038/nrn1687, 15928718.
49. Buemi M, Cavallaro E, Floccari F, Sturiale A, Aloisi C, Trimarchi M, Corica F, Frisina N. The pleiotropic effects of erythropoietin in the central nervous system. J Neuropathol Exp Neurol 2003, 62:228-236.
50. Fraser JK, Tan AS, Lin FK, Berridge MV. Expression of specific high-affinity binding sites for erythropoietin on rat and mouse megakaryocytes. Exp Hematol 1989, 17:10-16.
51. Jaquet K, Krause K, Tawakol-Khodai M, Geidel S, Kuck KH. Erythropoietin and VEGF exhibit equal angiogenic potential. Microvasc Res 2002, 64:326-333. 10.1006/mvre.2002.2426, 12204656.
52. Sela S, Shurtz-Swirski R, Sharon R, Manaster J, Chezar J, Shkolnik G, Shapiro G, Shasha SM, Merchav S, Kristal B. The polymorphonuclear leukocyte-a new target for erythropoietin. Nephron 2001, 88:205-210. 10.1159/000045991, 11423750.
53. Cao Z, Baguley BC, Ching LM. Interferon-inducible protein 10 induction and inhibition of angiogenesis in vivo by the antitumor agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA). Cancer Res 2001, 61:1517-1521.
54. Lotze MT. Interleukin 12: cellular and molecular immunology of an important regulatory cytokine. Introduction. Ann N Y Acad Sci 1996, 795:xiii-xix.
55. Atkins MB, Robertson MJ, Gordon M, Lotze MT, DeCoste M, DuBois JS, Ritz J, Sandler AB, Edington HD, Garzone PD, Mier JW, Canning CM, Battiato L, Tahara H, Sherman ML. Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies. Clin Cancer Res 1997, 3:409-417.
56. Del Vecchio M, Bajetta E, Canova S, Lotze MT, Wesa A, Parmiani G, Anichini A. Interleukin-12: biological properties and clinical application. Clin Cancer Res 2007, 13:4677-4685. 10.1158/1078-0432.CCR-07-0776, 17699845.
57. Krieg AM, Efler SM, Wittpoth M, Al Adhami MJ, Davis HL. Induction of systemic TH1-like innate immunity in normal volunteers following subcutaneous but not intravenous administration of CPG 7909, a synthetic B-class CpG oligodeoxynucleotide TLR9 agonist. J Immunother 2004, 27:460-471. 10.1097/00002371-200411000-00006, 15534490.
58. Murphy KM, Ouyang W, Farrar JD, Yang J, Ranganath S, Asnagli H, Afkarian M, Murphy TL. Signaling and transcription in T helper development. Annu Rev Immunol 2000, 18:451-494. 10.1146/annurev.immunol.18.1.451, 10837066.
59. Pertl U, Luster AD, Varki NM, Homann D, Gaedicke G, Reisfeld RA, Lode HN. IFN-gamma-inducible protein-10 is essential for the generation of a protective tumor-specific CD8 T cell response induced by single-chain IL-12 gene therapy. J Immunol 2001, 166:6944-6951.
60. Vicari AP, Schmalbach T, Lekstrom-Himes J, Morris ML, Al-Adhami MJ, Laframboise C, Leese P, Krieg AM, Efler SM, Davis HL. Safety, pharmacokinetics and immune effects in normal volunteers of CPG 10101 (ACTILON), an investigational synthetic toll-like receptor 9 agonist. Antivir Ther 2007, 12:741-751.
61. Zou JP, Yamamoto N, Fujii T, Takenaka H, Kobayashi M, Herrmann SH, Wolf SF, Fujiwara H, Hamaoka T. Systemic administration of rIL-12 induces complete tumor regression and protective immunity: response is correlated with a striking reversal of suppressed IFN-gamma production by anti-tumor T cells. Int Immunol 1995, 7:1135-1145. 10.1093/intimm/7.7.1135, 8527411.
62. Coma G, Pena R, Blanco J, Rosell A, Borras FE, Este JA, Clotet B, Ruiz L, Parkhouse RM, Bofill M. Treatment of monocytes with interleukin (IL)-12 plus IL-18 stimulates survival, differentiation and the production of CXC chemokine ligands (CXCL)8, CXCL9 and CXCL10. Clin Exp Immunol 2006, 145:535-544. 10.1111/j.1365-2249.2006.03145.x, 1809701, 16907924.
63. Lee TV, Kim DK, Peoples GE, Castilleja A, Murray JL, Gershenson DM, Ioannides CG. Secretion of CXC chemokine IP-10 by peripheral blood mononuclear cells from healthy donors and breast cancer patients stimulated with HER-2 peptides. J Interferon Cytokine Res 2000, 20:391-401. 10.1089/107999000312333, 10805374.
64. Gluzman-Poltorak Z, Mendonca SR, Vainstein V, Kha H, Basile LA. Randomized comparison of single dose of recombinant human IL-12 versus placebo for restoration of hematopoiesis and improved survival in rhesus monkeys exposed to lethal radiation. J Hematol Oncol 2014, 7:31. doi:10.1186/1756-8722-7-31, 10.1186/1756-8722-7-31, 24708888.
65. Basile LA, Gallaher TK, Shibata D, Miller JD, Douer D. Multilineage hematopoietic recovery with concomitant antitumor effects using low dose Interleukin-12 in myelosuppressed tumor-bearing mice. J Transl Med 2008, 6:26. 10.1186/1479-5876-6-26, 2424034, 18489769.